C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 814—Premarket Approval of Medical DevicesSubpart C—Fda Action on a Pma

21 C.F.R. § 814.44 (2026)

Procedures for review of a PMA

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1994–2023 23citing cases
At a glance

Courts have cited this section in 23 opinions since 1994, 1 of them in the last five years.

(a) FDA will begin substantive review of a PMA after the PMA is accepted for filing under § 814.42. FDA may refer the PMA to a panel on its own initiative, and will do so upon request of an applicant, unless FDA determines that the application substantially duplicates information previously reviewed by a panel. If FDA refers an application to a panel, FDA will forward the PMA, or relevant portions thereof, to each member of the appropriate FDA panel for review. During the review process, FDA may communicate with the applicant as set forth under § 814.37(b), or with a panel to respond to questions that may be posed by panel members or to provide additional information to the panel. FDA will maintain a record of all communications with the applicant and with the panel.

(b) The advisory committee shall submit a report to FDA which includes the committee's recommendation and the basis for such recommendation on the PMA. Before submission of this report, the committee shall hold a public meeting to review the PMA in accordance with part 14. This meeting may be held by a telephone conference under § 14.22(g). The advisory committee report and recommendation may be in the form of a meeting transcript signed by the chairperson of the committee.

(c) FDA will complete its review of the PMA and the advisory committee report and recommendation and, within the later of 180 days from the date of filing of the PMA under § 814.42 or the number of days after the date of filing as determined under § 814.37(c), issue an approval order under paragraph (d) of this section, an approvable letter under paragraph (e) of this section, a not approvable letter under paragraph (f) of this section, or an order denying approval of the application under § 814.45(a).

(d)(1) FDA will issue to the applicant an order approving a PMA if none of the reasons in § 814.45 for denying approval of the application applies. FDA will approve an application on the basis of draft final labeling if the only deficiencies in the application concern editorial or similar minor deficiencies in the draft final labeling. Such approval will be conditioned upon the applicant incorporating the specified labeling changes exactly as directed and upon the applicant submitting to FDA a copy of the final printed labeling before marketing. FDA will also give the public notice of the order, including notice of and opportunity for any interested persons to request review under section 515(d)(4) of the act. The notice of approval will be placed on FDA's home page on the Internet (http://www.fda.gov), and it will state that a detailed summary of information respecting the safety and effectiveness of the device, which was the basis for the order approving the PMA, including information about any adverse effects of the device on health, is available on the Internet and has been placed on public display, and that copies are available upon request. When a notice of approval is published, data and information in the PMA file will be available for public disclosure in accordance with § 814.9.

(2) A request for copies of the current PMA approvals and denials document and for copies of summaries of safety and effectiveness shall be sent in writing to the Freedom of Information Staff's address listed on the Agency's website at https://www.fda.gov.

(e) FDA will send the applicant an approvable letter if the application substantially meets the requirements of this part and the agency believes it can approve the application if specific additional information is submitted or specific conditions are agreed to by the applicant.

(1) The approvable letter will describe the information FDA requires to be provided by the applicant or the conditions the applicant is required to meet to obtain approval. For example, FDA may require, as a condition to approval:

(i) The submission of certain information identified in the approvable letter, e.g., final labeling;

(ii) The submission of additional information concerning pediatric uses required by § 814.20(b)(13);

(iii) An FDA inspection that finds the manufacturing facilities, methods, and controls in compliance with part 820 and, if applicable, that verifies records pertinent to the PMA;

(iv) Restrictions imposed on the device under section 515(d)(1)(B)(ii) or 520(e) of the act;

(v) Postapproval requirements as described in subpart E of this part.

(2) In response to an approvable letter the applicant may:

(i) Amend the PMA as requested in the approvable letter; or

(ii) Consider the approvable letter to be a denial of approval of the PMA under § 814.45 and request administrative review under section 515(d)(4) of the act by filing a petition in the form of a petition for reconsideration under § 10.33; or

(iii) Withdraw the PMA.

(f) FDA will send the applicant a not approvable letter if the agency believes that the application may not be approved for one or more of the reasons given in § 814.45(a). The not approvable letter will describe the deficiencies in the application, including each applicable ground for denial under section 515(d)(2) (A)-(E) of the act, and, where practical, will identify measures required to place the PMA in approvable form. In response to a not approvable letter, the applicant may:

(1) Amend the PMA as requested in the not approvable letter (such an amendment will be considered a major amendment under § 814.37(c)(1)); or

(2) Consider the not approvable letter to be a denial of approval of the PMA under § 814.45 and request administrative review under section 515(d)(4) of the act by filing a petition in the form of a petition for reconsideration under § 10.33; or

(3) Withdraw the PMA.

(g) FDA will consider a PMA to have been withdrawn voluntarily if:

(1) The applicant fails to respond in writing to a written request for an amendment within 180 days after the date FDA issues such request;

(2) The applicant fails to respond in writing to an approvable or not approvable letter within 180 days after the date FDA issues such letter; or

(3) The applicant submits a written notice to FDA that the PMA has been withdrawn.

[51 FR 26364, July 22, 1986, as amended at 57 FR 58403, Dec. 10, 1992; 63 FR 4572, Jan. 30, 1998; 79 FR 1740, Jan. 10, 2014; 87 FR 2045, Jan. 13, 2022]
The 20 cases that cite 21 C.F.R. § 814.44 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENRiegel v. Medtronic, Inc., 451 F.3d 104 (2d Cir. 2006).
cites § 814.44 9×cited by 104 cases
Where it cites § 814.44
“21 C.F.R. § 814.44 ; see also www.fda.gov/cdrh/devadvice/pma (“Review Process: Overview”) (last visited April 28, 2006).”
The case’s holding
State common law tort claims alleging liability based on a medical device's adherence to FDA premarket approval standards are preempted by the Medical Device Amendments.
Later courts cite it for
“an expert opinion requires some explanation as to how the expert came to his conclusion and what methodologies or evidence substantiate that conclusion.” · 26 citing courts
2
GREENRiegel v. Medtronic, Inc., 552 U.S. 312 (2008).
cites § 814.44 4×cited by 725 cases
Where it cites § 814.44
“Before deciding whether to approve the application, the agency may refer it to a panel of outside experts, 21 CFR § 814.44 (a) (2007), and may request additional data from the manufacturer, § 360e(c)(1)(G).”
The case’s holding
The Medical Device Amendments preclude state law claims that impose requirements different from, or in addition to, federal requirements regarding a device that received premarket approval.
Later courts cite it for
“360k does not prevent a state from providing a damages remedy for claims premised on a violation of fda regulations; the state duties in such a case 'parallel,' rather than add to, federal requirements.” · 102 citing courts
3
GREENVicky Nguyen v. Endologix, Inc., 962 F.3d 405 (9th Cir. 2020).
cites § 814.44 1×cited by 90 cases
Where it cites § 814.44
“See generally 21 C.F.R. § 814.44 . An analyst asked whether the prospect of this referral had been driven by any “sort of red flag raised in terms of data” submitted to the FDA.”
The case’s holding
To plead scienter under the PSLRA, a plaintiff must allege facts giving rise to a strong inference of intent to deceive that is at least as compelling as any innocent inference.
Later courts cite it for
“if defendants had sought to profit from this scheme in the interim, such as by selling off their stock or selling the company at a premium, the theory might have more legs.” · 4 citing courts
4
GREENCaplinger v. Medtronic, Inc., 921 F. Supp. 2d 1206 (W.D. Okla. 2013).
cites § 814.44 2×cited by 37 cases
Where it cites § 814.44
“s safety and effectiveness that have been published or should reasonably be known to the applicant; a “full statement” of the device’s “components, ingredients, and properties and of the principle or principles of operation”; “a full description of the methods used in, and the…”
The case’s holding
State law claims based on off-label promotion are impliedly preempted because the concept of off-label use is defined by federal law rather than state substantive law.
Later courts cite it for
“even the concept of 'off-label use' is a creature of the fdca, is defined by the fdca, and is not a part of oklahoma substantive law” · 8 citing courts
5
GREENRiley v. Cordis Corp., 625 F. Supp. 2d 769 (D. Minn. 2009).
cites § 814.44 1×cited by 110 cases
Where it cites § 814.44
“Before deciding whether to approve the application, the agency may refer it to a panel of outside experts, 21 CFR § 814.44 (a)(2007), and may request additional data from the manufacturer, § 360e(c)(l)(G).”
The case’s holding
A state-law claim survives preemption only if it is premised on conduct that violates the FDCA and would give rise to a recovery under state law without the FDCA.
Later courts cite it for
“must be the type of conduct that would traditionally give rise to liability under state law-and that would give rise to liability under state law even if the fdca had never been enacted.” · 8 citing courts
6
GREENWhite v. Stryker Corp., 818 F. Supp. 2d 1032 (W.D. Ky. 2011).
cites § 814.44 2×cited by 18 cases
Where it cites § 814.44
“See 21 C.F.R. § 814.44 . Indeed, the FDA referred the Trident System application to the Orthopedic and Rehabilitation Advisory Committee on July 20, 2000.”
Later courts cite it for
“a plausible cause of action requires, among other things, a showing that the alleged violation of state law parallels a violation of federal law.” · 2 citing courts
7
GREENBlunt v. Medtronic, Inc., 2009 WI 16, 760 N.W.2d 396.
cites § 814.44 2×cited by 17 cases
Where it cites § 814.44
“Before deciding whether to approve the application, the agency may refer it to a panel of outside experts, 21 C.F.R. § 814.44 (a) (2007), and may request additional data from the manufacturer, § 360e(c)(1)(G).”
The case’s holding
State tort claims challenging the safety of a Class III medical device are expressly preempted where the device received device-specific FDA premarket approval, absent withdrawal of that approval.
Later courts cite it for
“we review a summary judgment decision independently, employing the same methodology as the circuit court,” · 2 citing courts
8
GREENConklin v. Medtronic Inc, 431 P.3d 571 (Ariz. 2018).
cites § 814.44 1×cited by 15 cases
Where it cites § 814.44
“1012 (noting that PMA review "involves a time-consuming inquiry into the risks and efficacy of each device"); 21 C.F.R. § 814.44 (a). Medtronic's Pain Pump is a Class III device.”
Later courts cite it for
“watts adopted the restatement (third) of torts provision in 6(d) that 8 sets forth the doctrine for prescription drug and medical device manufacturers.” · 2 citing courts
9
GREENElizabeth & Clifford Kemp v. Medtronic, Inc., 231 F.3d 216 (6th Cir. 2000).
cites § 814.44 1×cited by 107 cases
The case’s holding
FDA approval of a premarket approval supplement and its accompanying conditions constitute specific federal requirements that preempt state law claims under the Medical Device Amendments.
Later courts cite it for
“to the extent that plaintiffs' claim is premised on the adequacy of the warnings reviewed and approved by the fda . . . the claim is . . . preempted.” · 5 citing courts
10
GREENBlanco v. Baxter Healthcare Corp., 158 Cal. App. 4th 1039 (Ct. App. 2008).
cites § 814.44 1×cited by 31 cases
Where it cites § 814.44
“§ 360e(d); 21 C.F.R. § 814.44 (c) (2007).) FDA approval of a PMA does not end its oversight of the class III device.”
The case’s holding
State common law tort claims challenging the manufacture or labeling of a device approved through FDA premarket approval are preempted by the Medical Device Amendments because they impose different requirements.
Later courts cite it for
“the fact that the fda implemented a class i recall of the medical device does not alter our conclusion that plaintiffs claims are preempted.” · 1 citing court
11
GREENWorthy v. Collagen Corp., 967 S.W.2d 360 (Tex. 1998).
cites § 814.44 1×cited by 68 cases
Where it cites § 814.44
“§ 360e(d)(2); see also 21 C.F.R. § 814.44 . A device approved for marketing cannot be “manufactured, packaged, stored, labeled, distributed, or advertised in a manner that is inconsistent with any conditions to approval specified in the PMA approval order for the device.”
The case’s holding
State law claims alleging liability despite a medical device's adherence to FDA-approved standards are preempted by federal requirements.
Later courts cite it for
“while a federal requirement would ordinarily not preempt general state common law requirements such as a duty of care or a duty to warn in the abstract, a federal requirement would preempt a particularized application of such duties that imposed a specific 'standard of care or behavior' different or in addition to the federal requirement.” · 3 citing courts
12
GREENMcCormick v. Medtronic, Inc., 101 A.3d 467 (Md. Ct. Spec. App. 2014).
cites § 814.44 1×cited by 19 cases
The case’s holding
Claims under Maryland's consumer protection statute that do not sound in fraud are not subject to the heightened particularity pleading requirement applicable to fraud claims.
Later courts cite it for
“although rule 2-305 generally requires that a complaint contain only 'a clear statement of the facts necessary to constitute a cause of action,' maryland courts have long required parties to plead fraud with particularity.” · 3 citing courts
13
GREENMcPhee v. DePuy Orthopedics, Inc., 989 F. Supp. 2d 451 (W.D. Pa. 2012).
cites § 814.44 1×cited by 14 cases
Where it cites § 814.44
“Once a device receives premarket approval, “the MDA forbids the manufacturer to make, without FDA permission, changes in design specifications, manufacturing processes, labeling, or any other attribute, that would affect safety or effectiveness.”
Later courts cite it for
“some form of promise or affirmative statement.” · 2 citing courts
14
GREENContratto v. Ethicon, Inc., 227 F.R.D. 304 (N.D. Cal. 2005).
cites § 814.44 1×cited by 13 cases
Summary
No passage or summary on file for this case yet.
15
GREENDESABIO v. Howmedica Osteonics Corp., 817 F. Supp. 2d 197 (W.D.N.Y. 2011).
cites § 814.44 1×cited by 7 cases
Where it cites § 814.44
“Premarket ap7 proval is granted only if the FDA finds there is a reasonable assurance of the device’s safety and effectiveness.”
16
GREENMilkiewicz v. Baxter Healthcare Corp., 963 F. Supp. 1150 (M.D. Fla. 1996).
cites § 814.44 2×cited by 4 cases
Where it cites § 814.44
“” 21 C.F.R. § 814.44 (d). An applicant seeking PMA approval must include with its application copies of all proposed labeling for the device, which may include instructions for installation and any information constituting labeling.”
17
GREENStanfield v. Boston Sci. Corp., 166 F. Supp. 3d 873 (S.D. Tex. 2015).
cites § 814.44 1×cited by 3 cases
Where it cites § 814.44
“Before deciding whether to approve the application, the agency may refer it to a panel of outside experts, 21 CFR § 814.44 (a)(2007), and may request additional data from the manufacturer.”
18
GREENHinkel v. St. Jude Med., S.C., Inc., 869 F. Supp. 2d 739 (E.D. La. 2012).
cites § 814.44 1×cited by 3 cases
Where it cites § 814.44
“§ 360e(c)(1)(G); 21 C.F.R. § 814.44 (a)). The FDA must “weig[h] any probable benefit to health from the use of the device against any probable risk of injury or illness from such use” and may “thus approve devices that present great risks if they nonetheless offer great benefits…”
19
GREENIn re Guidant Corp. Implantable Defibrillators Prods. Liab. Litig., 428 F. Supp. 2d 1014 (D. Minn. 2006).
cites § 814.44 1×cited by 1 case
Summary
No passage or summary on file for this case yet.
20
NEUTRALFogal v. Steinfeld, 163 Misc. 2d 497 (N.Y. Sup. Ct. 1994).
cites § 814.44 2×cited by 3 cases
Where it cites § 814.44
“g, 21 USC § 360e [d] [A], [B], CD]; 21 CFR 814.44 [d], [e] [1] [i]; 814.80, 814.”

Show all 23 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199420082023

One bar per year. Tallest: 3 cases in 2011. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D. Minn.2Ariz.12d Cir.16th Cir.19th Cir.1Cal. Ct. App.1N.D. Cal.1M.D. Fla.1

The 8 courts with the most citing cases, of 22 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 23 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com